UPDATE 1-Samsung BioLogics said JV partner Biogen to exercise option by late June
May 17, 2018 at 19:40 PM EDT
SEOUL, May 18 (Reuters) - South Korean drugmaker Samsung BioLogics said on Friday joint venture partner Biogen would exercise its call option to increase its stake to 50 percent minus one share in Samsung Bioepis.
